Selective Growth Hormone Secretagogue
A pentapeptide GH secretagogue that selectively stimulates the pituitary gland to release growth hormone in a natural, pulsatile pattern. Unlike direct GH administration, Ipamorelin works within the body's own regulatory system — producing GH release without affecting cortisol, prolactin, or ACTH. Considered the cleanest and most selective GH secretagogue available.
01 — Research Summary
Ipamor-elin has developed a substantial research portfolio across multiple domains. The evidence base spans animal models, cell studies, and in some cases early human data — providing a multi-layered picture of this compound's mechanisms and potential applications.
Clean, selective GH pulse. Ipamorelin produces a robust GH pulse within 60–90 minutes of administration with no measurable effect on cortisol, prolactin, or ACTH — making it uniquely clean among GH secretagogues in this respect.
Body composition improvements. Subjects on Ipamorelin protocols demonstrated increased lean muscle mass and reduced adiposity over 12-week study periods, consistent with the expected effects of elevated GH and downstream IGF-1.
Bone mineral density. Ipamorelin administration increased bone mineral density in animal models through GH/IGF-1 pathway activation — relevant for anti-aging and osteoporosis prevention applications.
GH-mediated sleep improvement. Consistent with GH's role in slow-wave sleep regulation, Ipamorelin users report significant improvements in sleep depth and quality — one of the most consistently cited benefits in both research and community reports.
Selective ghrelin receptor agonism. Ipamorelin acts specifically at the GHS-R1a (growth hormone secretagogue receptor) in the pituitary without meaningful off-target receptor activity — the pharmacological basis for its clean side effect profile.
02 — Mechanism of Action
Understanding the mechanism helps explain why Ipamor-elin produces the range of effects documented in both research and community reports. The compound operates through several interconnected pathways simultaneously.
Ipamorelin binds selectively to the growth hormone secretagogue receptor (GHS-R1a) in the anterior pituitary gland. This is the same receptor activated by ghrelin (the hunger hormone), but Ipamorelin has been engineered for selectivity without ghrelin's broad off-target effects.
GHS-R1a activation triggers a rapid, strong pulse of GH from pituitary somatotroph cells. Critically, this release is pulsatile — matching the body's natural GH secretion pattern — rather than the supraphysiological sustained elevation caused by exogenous HGH.
Released GH travels to the liver where it stimulates production of Insulin-like Growth Factor 1 (IGF-1) — the primary mediator of GH's anabolic effects on muscle, bone, and connective tissue. IGF-1 elevation persists longer than the GH pulse itself.
Unlike older GH secretagogues (GHRP-6, GHRP-2), Ipamorelin does not activate receptors that trigger cortisol or prolactin release. This selectivity is its key clinical advantage — pure GH stimulation without stress hormone side effects.
Ipamorelin works within the body's natural GH regulatory system, which includes somatostatin feedback. This means the body retains its ability to regulate GH — preventing the receptor downregulation and feedback suppression seen with exogenous HGH.
The multi-pathway mechanism of Ipamor-elin explains its broad range of documented effects. Rather than acting on a single target, it engages multiple biological systems simultaneously — which is both the source of its versatility and the reason dosing and cycling matter.
03 — Dosing Protocols
The following protocols are drawn from published research literature and community-reported experience. Individual responses vary significantly. Always start at the lower end of the dose range.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard — body composition | 200–300 mcg | 2–3× daily | 12–16 weeks | Inject fasted. Morning, pre-workout, and/or before bed. Avoid carbs 30 min post-injection. |
| Sleep optimisation | 100–200 mcg | 1× before bed | Ongoing | Single bedtime injection to enhance slow-wave sleep GH pulse. Most conservative protocol. |
| Stacked with CJC-1295 | 100–200 mcg | 2× daily | 12–16 weeks | Reduce Ipamorelin dose when stacking — CJC-1295 amplifies the GH response. |
| Anti-aging / longevity | 100–150 mcg | 1× daily at bed | 12 weeks on / 4 off | Conservative longevity protocol. Focus on sleep, recovery, and GH normalisation. |
| High-performance | 300 mcg | 3× daily | 12 weeks | Maximum commonly used dose. Fasted injections critical. Full protocol for competitive athletes. |
Timing is critical: Ipamorelin should always be injected in a fasted state — ideally 2+ hours after food. Carbohydrates blunt the GH pulse significantly. Avoid eating for 30–60 minutes post-injection. Cycling: 12–16 week cycles followed by 4–8 week breaks is the standard protocol. Reconstitution: Add 2 mL bacteriostatic water per vial. Refrigerate at 2–8°C, use within 28 days.
All dosing information is drawn from published research and community protocols for educational purposes only. Ipamor-elin is not FDA-approved for human therapeutic use. Consult a licensed healthcare professional before initiating any peptide protocol.
04 — Community Experiences
Ipamorelin is among the most popular peptides in the community and consistently receives high ratings across multiple use cases. It is most commonly discussed in the context of the CJC-1295 stack, sleep quality, and anti-aging protocols. Its clean side effect profile relative to older GH secretagogues is a recurring theme. The following links surface real discussions from public research and wellness communities. These are anecdotal reports — not clinical evidence — and results vary significantly between individuals.
These are user-reported experiences from public forums. They are not endorsed by Whats That Peptide and should not be interpreted as clinical evidence of efficacy or safety. Individual results vary. Always consult a healthcare professional before starting any peptide protocol.
"Week 1–2: nothing. Week 3: deeper sleep but groggy. Week 4 onwards: the best sleep of my adult life. I'm waking up genuinely recovered in a way I haven't experienced in years. The dreams are vivid and the morning energy is real..."
"The stack is greater than the sum of parts. Ipamorelin alone gave me maybe 60% of the results. Adding CJC pushed it well beyond. Body composition changes became visible around week 8 and kept improving through week 20..."
"IGF-1 went from 98 to 147 ng/mL. Lean mass up measurably for first time in years. Recovery from training is dramatically better. My endocrinologist is cautiously supportive and monitoring labs quarterly..."
"Water retention in week 1–2, some tingling, mild headaches. All resolved by week 3. The key is starting low — 100 mcg — and building up. People who complain of persistent side effects are usually dosing too high too fast..."